← Leaderboards
Julio Alonso Chirinos Medina
University Of Pennsylvania
$12,868,016
Attributed
$16,153,660
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,153,660 · 10
By mechanism
R01$8,420,372 · 3
U01$3,131,479 · 2
R33$2,189,080 · 1
K24$974,775 · 1
R56$594,491 · 1
R21$440,000 · 1
Top collaborators
- Anne R Cappola4 shared
- Thomas P Cappola4 shared
- Jordana B. Cohen4 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Payman Zamani$8,078,139
- Theresa M Busch$13,382,890
- Thomas P Cappola$16,895,234
- Jordana B. Cohen$7,481,237
- Robert B Wilson$8,097,885
Others in their field
Top investigators on “Heart Failure”
- Judith S Hochman · New York University School Of Medicine$120,321,606
- David T Mauger · Pennsylvania State Univ Hershey Med Ctr$51,947,333
- Lisa P Jacobson · Johns Hopkins University$45,397,923
- Walter N Kernan · Yale University$42,197,025
- Dalane W Kitzman · Wake Forest University$40,701,149
- David Couper · Univ Of North Carolina Chapel Hill$37,959,091
Research focus
Heart FailureResearch PersonnelBlood VesselsVentricularEnrollmentProspectiveAdultEfracMediatingFibrosisMagnetic Resonance ImagingRandomizedLeftCardiacTissuesArterial TonometryHeartResponseCardiovascular SystemPublic HealthRestQuality Of LifeEchocardiographyPhenotype
Grant awards (32)
Cardiovascular Risk, Vascular and Kidney Damage in COVID-19 Survivors$759,634
R01 · FY2025 · HL · contact PI
HeartShare: Next-Generation Phenomics to Define Heart Failure Subtypes and Treatment Targets - Clinical Centers$253,713
U01 · FY2025 · HL · contact PI
Genetic determinants of thoracic aortic stiffness and remodeling$194,955
K24 · FY2025 · AG · contact PI
Cardiovascular Risk, Vascular and Kidney Damage in COVID-19 Survivors$759,344
R01 · FY2024 · HL · contact PI
HeartShare: Next-Generation Phenomics to Define Heart Failure Subtypes and Treatment Targets - Clinical Centers$264,373
U01 · FY2024 · HL · contact PI
Genetic determinants of thoracic aortic stiffness and remodeling$194,955
K24 · FY2024 · AG · contact PI
Cardiovascular Risk, Vascular and Kidney Damage in COVID-19 Survivors$792,262
R01 · FY2023 · HL · contact PI
HeartShare: Next-Generation Phenomics to Define Heart Failure Subtypes and Treatment Targets - Clinical Centers$271,427
U01 · FY2023 · HL · contact PI
Genetic determinants of thoracic aortic stiffness and remodeling$194,955
K24 · FY2023 · AG · contact PI
Cardiovascular Risk, Vascular and Kidney Damage in COVID-19 Survivors$803,324
R01 · FY2022 · HL · contact PI
Developing Oral LT3 Therapy for Heart Failure$663,317
R33 · FY2022 · HL
HeartShare: Next-Generation Phenomics to Define Heart Failure Subtypes and Treatment Targets - Clinical Centers$278,480
U01 · FY2022 · HL · contact PI
Genetic determinants of thoracic aortic stiffness and remodeling$194,955
K24 · FY2022 · AG · contact PI
Efficacy of Fenofibrate for COVID-19: A phase II randomized controlled trial$1,328,303
U01 · FY2021 · TR · contact PI
Developing Oral LT3 Therapy for Heart Failure$755,779
R33 · FY2021 · HL
Efficacy of Fenofibrate for COVID-19: A phase II randomized controlled trial$448,476
U01 · FY2021 · TR · contact PI
HeartShare: Next-Generation Phenomics to Define Heart Failure Subtypes and Treatment Targets - Clinical Centers$286,707
U01 · FY2021 · HL · contact PI
Genetic determinants of thoracic aortic stiffness and remodeling$194,955
K24 · FY2021 · AG · contact PI
Developing Oral LT3 Therapy for Heart Failure$769,984
R33 · FY2020 · HL
Efficacy of Potassium Nitrate in Heart Failure with Preserved Ejection Fraction$612,510
R01 · FY2019 · HL · contact PI
Developing Oral LT3 Therapy for Heart Failure$403,463
R61 · FY2019 · HL
Efficacy of Potassium Nitrate in Heart Failure with Preserved Ejection Fraction$634,064
R01 · FY2018 · HL · contact PI
Efficacy of Potassium Nitrate in Heart Failure with Preserved Ejection Fraction$618,654
R01 · FY2017 · HL · contact PI
Efficacy of Potassium Nitrate in Heart Failure with Preserved Ejection Fraction$618,771
R01 · FY2016 · HL · contact PI
Efficacy of Potassium Nitrate in Heart Failure with Preserved Ejection Fraction$638,264
R01 · FY2015 · HL · contact PI
Targeting Central Pulsatile Hemodynamics in Chronic Kidney Disease$594,491
R56 · FY2015 · HL · contact PI
Targeting Wave Reflections in Heart Failure with Preserved Ejection Fraction$160,000
R21 · FY2014 · AG · contact PI
Targeting Wave Reflections in Heart Failure with Preserved Ejection Fraction$280,000
R21 · FY2013 · AG · contact PI
Inflammatory response to sleep apnea in obese subjects$603,495
R01 · FY2010 · HL · contact PI
Inflammatory response to sleep apnea in obese subjects$706,674
R01 · FY2009 · HL · contact PI
Inflammatory response to sleep apnea in obese subjects$182,814
R01 · FY2009 · HL · contact PI
Inflammatory response to sleep apnea in obese subjects$690,562
R01 · FY2008 · HL · contact PI